Skip to content

To determine if addition of Dexmedtomidine to Bupivacaine used in Femoral Nerve Block will enhance duration of post operative analgesia

Efficacy of Dexmedetomidine as an adjuvant to 0.25% Bupivacaine in Ultrasound guided Femoral Nerve Block for Pre-operative positioning and Post-operative Analgesia in patients undergoing elective surgery for Femoral shaft fracture - FNB

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026467
Enrollment
70
Registered
2020-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S723- Fracture of shaft of femur

Interventions

Intervention1: Femoral Nerve Block: Femoral Nerve Block for providing comfort of positioning for subarachnoid block and provide Post operative analgesia Control Intervention1: Dexmedetomidine: Dexmede

Sponsors

Vijayanagara Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Grade I & II

Exclusion criteria

Exclusion criteria: 1 Allergy to Study Drug 2 History of significant systemic disease ( n Cardiovascular, Respiratory, Central Nervous System, Renal System ) 3 Cognitive Dysfunction 4 Emergency Surgeries 5 Patients with Spinal Deformities, Bleeding Diasthesis 6 Local Skin Site Infection 7 Refusal by patients for procedure

Design outcomes

Primary

MeasureTime frame
To determine patient comfort for positioning for spinal anaesthesia and Duration of post operative analgesiaTimepoint: From start of procedure until 24 hrs post operative

Secondary

MeasureTime frame
1 Onset, Duration, Level of sensory Block 2 Onset, Duration of motor Block 3 Side effects like Hypotension, Bradycardia, Respiratory Depression etc.Timepoint: From start of procedure until 24 hrs postoperative

Countries

India

Contacts

Public ContactDr Vinod M

Vijayanagara Institute of Medical Sciences, Ballari

dr.devanand.b@gmail.com9845233239

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026